After Hours
$
103.02
Change
+0.07 +0.07%
Volume
Volume 760,946
Sep 29, 2023, 7:57 p.m.
Quotes are delayed by 20 min
Previous close
$ 104.30
$ 102.95
Change
-1.35 -1.29%
Day low
Day high
$102.71
$104.68

52 week low
52 week high
$86.02
$119.65

Market cap
$261.24B
Average volume
6.69M
P/E ratio
84.77
Rev. per Employee
$831,203
EPS
1.21
Dividend
0.73
Div yield
2.84%
Ex dividend date
9/14/23
MarketWatch News on MRK
-
3M, Merck share losses lead Dow's nearly 100-point drop
- MarketWatch Automation
-
Merck and Eisai says they are disappointed with trial results but will continue to research the disease
- Ciara Linnane
-
Merck and Eisai offer update on 2 Phase 3 trials of Keytruda and Lenvima in patients with certain types of metastatic non-small lung cancer
- Ciara Linnane
-
Merck and Eisai say both trials missed their main goals
- Ciara Linnane
-
New Cancer Drugs Are Changing the Odds of Survival
- Neal Templin
-
'This Is Not a Covid Vaccine Company,' Moderna CEO Says
- Josh Nathan-Kazis
-
Moderna Stock Rises on Positive Results From Flu Vaccine
- Angela Palumbo
-
Moderna aims to prove it’s ‘more than a COVID company’
- Eleanor Laise
-
These four Dow stocks take top prizes for dividend growth
- Philip van Doorn
-
Apple, Merck share losses lead Dow's 175-point drop
- MarketWatch Automation
-
Dow drops 88 points on losses for shares of Merck, Johnson & Johnson
- MarketWatch Automation
-
First 10 Drugs Picked for Medicare Price Negotiations
- Bill Alpert
- Loading more headlines...
Analyst Ratings
-
Analysts Cut Target Prices on MYL Stock after Its Q2 2018 Results
- MarketRealist.com
-
Amgen Stock in May: A Substantial Rise
- MarketRealist.com
-
Analysts’ Recommendations for Merck, Post-1Q18 Results
- MarketRealist.com
Other News on MRK
-
How Research in Space Helps Doctors Treat People on Earth
- The Wall Street Journal Interactive Edition
-
Big Pharma’s Battle With the Biden Administration Could Have Legs
- The Wall Street Journal Interactive Edition
-
How Novartis’s CEO Learned From Mistakes and Got Help From an Unlikely Quarter
- The Wall Street Journal Interactive Edition
-
Expensive Drugs Targeted for First U.S. Price Negotiations
- The Wall Street Journal Interactive Edition
-
Get In on This Skin Disease Drug Before Big Pharma Does
- The Wall Street Journal Interactive Edition
-
- The Wall Street Journal Interactive Edition
-
Apple, Amazon, Starbucks to Report in Packed Earnings Week
- The Wall Street Journal Interactive Edition
-
- The Wall Street Journal Interactive Edition
-
Companies Brace for Supreme Court Ruling on Affirmative Action
- The Wall Street Journal Interactive Edition
-
Chamber of Commerce Challenges Government’s Drug-Price Powers
- The Wall Street Journal Interactive Edition
-
Merck Sues to Stop the IRA’s ‘Extortion’
- The Wall Street Journal Interactive Edition
-
Merck Challenges U.S. Government’s New Powers to Negotiate Drug Prices
- The Wall Street Journal Interactive Edition
-
Top Morgan Stanley M&A Banker to Join Law Firm Paul Weiss
- The Wall Street Journal Interactive Edition
-
New Pfizer RSV Vaccine Rolls Out Into Headwinds of Hesitancy
- The Wall Street Journal Interactive Edition
-
As Borrowing Costs Rise, Big Companies Get the Upper Hand
- The Wall Street Journal Interactive Edition
-
Virtual Fences for Cattle Find a Home on the Range
- The Wall Street Journal Interactive Edition
-
FTC’s Amgen Activism Will Spare Smaller Biotechs
- The Wall Street Journal Interactive Edition
-
- Edgar Online - (EDG = 10Q, 10K)
-
Merck’s Insurers On the Hook in $1.4 Billion NotPetya Attack, Says Court
- The Wall Street Journal Interactive Edition
-
Starbucks, Ford, Apple Lead Another Busy Earnings Week
- The Wall Street Journal Interactive Edition
- Loading more headlines...
Press Releases on MRK
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com